CYTK
Price
$67.92
Change
-$6.06 (-8.19%)
Updated
Mar 4, 1:07 PM EST
59 days until earnings call
FATE
Price
$7.17
Change
-$0.57 (-7.36%)
Updated
Mar 4, 1:36 PM EST
58 days until earnings call
Ad is loading...

CYTK vs FATE ᐉ Comparison: Which is Better to Invest?

Header iconCYTK vs FATE Comparison
Open Charts CYTK vs FATEBanner chart's image
Cytokinetics
Price$67.92
Change-$6.06 (-8.19%)
Volume$362
CapitalizationN/A
Fate Therapeutics
Price$7.17
Change-$0.57 (-7.36%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
CYTK vs FATE Comparison Chart

Loading...

CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
FATEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CYTK vs. FATE commentary
Mar 04, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and FATE is a StrongSell.

COMPARISON
Comparison
Mar 04, 2024
Stock price -- (CYTK: $73.98 vs. FATE: $7.74)
Brand notoriety: CYTK and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 33% vs. FATE: 60%
Market capitalization -- CYTK: $7.25B vs. FATE: $768.1M
CYTK [@Biotechnology] is valued at $7.25B. FATE’s [@Biotechnology] market capitalization is $768.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $550.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 2 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CYTK’s FA Score: 2 green, 3 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 3 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • CYTK’s TA Score: 3 bullish, 5 bearish.
  • FATE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, FATE is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а -5.18% price change this week, while FATE (@Biotechnology) price change was +11.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.37%. For the same industry, the average monthly price growth was +19.14%, and the average quarterly price growth was +52.89%.

Reported Earning Dates

CYTK is expected to report earnings on May 02, 2024.

FATE is expected to report earnings on May 01, 2024.

Industries' Descriptions

@Biotechnology (+4.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CYTK with price predictions.
OPEN
A.I.dvisor published
a Summary for FATE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CYTK($7.25B) has a higher market cap than FATE($768M). FATE YTD gains are higher at: 106.952 vs. CYTK (-11.391). FATE has higher annual earnings (EBITDA): -172.23M vs. CYTK (-462.64M). CYTK has more cash in the bank: 539M vs. FATE (315M). FATE has less debt than CYTK: FATE (104M) vs CYTK (748M). FATE has higher revenues than CYTK: FATE (63.5M) vs CYTK (7.82M).
CYTKFATECYTK / FATE
Capitalization7.25B768M945%
EBITDA-462.64M-172.23M269%
Gain YTD-11.391106.952-11%
P/E RatioN/AN/A-
Revenue7.82M63.5M12%
Total Cash539M315M171%
Total Debt748M104M719%
FUNDAMENTALS RATINGS
CYTK vs FATE: Fundamental Ratings
CYTK
FATE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
31
Undervalued
PROFIT vs RISK RATING
1..100
12100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3534
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (31) in the Biotechnology industry is significantly better than the same rating for CYTK (100). This means that FATE’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (12) in the Biotechnology industry is significantly better than the same rating for FATE (100). This means that CYTK’s stock grew significantly faster than FATE’s over the last 12 months.

FATE's SMR Rating (96) in the Biotechnology industry is in the same range as CYTK (100). This means that FATE’s stock grew similarly to CYTK’s over the last 12 months.

FATE's Price Growth Rating (34) in the Biotechnology industry is in the same range as CYTK (35). This means that FATE’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for FATE (100). This means that CYTK’s stock grew significantly faster than FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKFATE
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
84%
Momentum
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 6 days ago
85%
MACD
ODDS (%)
N/A
Bearish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
74%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
86%
Aroon
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Ad is loading...
CYTKDaily Signal changed days agoGain/Loss if shorted
 
Show more...
FATEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NDIV27.330.34
+1.25%
Amplify Natural Resources Div Inc ETF
ISRA37.880.34
+0.92%
VanEck Israel ETF
DFUV38.980.25
+0.65%
Dimensional US Marketwide Value ETF
BSMO24.800.04
+0.16%
Invesco BulletShares (R) 2024MuncplBdETF
WCLD35.800.04
+0.11%
WisdomTree Cloud Computing ETF

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with TVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then TVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+2.41%
TVTX - CYTK
57%
Loosely correlated
+4.10%
BCAB - CYTK
47%
Loosely correlated
+5.56%
VBIV - CYTK
44%
Loosely correlated
+1.72%
EWTX - CYTK
44%
Loosely correlated
+2.20%
KRON - CYTK
43%
Loosely correlated
-1.92%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with NTLA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+9.17%
NTLA - FATE
51%
Loosely correlated
+1.68%
PIRS - FATE
51%
Loosely correlated
+4.78%
BEAM - FATE
49%
Loosely correlated
+0.89%
XNCR - FATE
48%
Loosely correlated
+3.79%
ADPT - FATE
48%
Loosely correlated
-1.95%
More